Real-World Impact of Tezepelumab on Asthma Exacerbations, Healthcare Resource Utilization, and Costs in US Patients with Severe Asthma: CROSSROADS-1
Journal of Asthma and Allergy · 2026-10 · Volume 19 · 1-15
DOI: 10.2147/jaa.s620862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Asthma and Allergy, 2026-10. Verfasst von Santiago Zuluaga Sanchez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics, Amgen Ltd, Uxbridge, UK. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Economics, Amgen Ltd, Uxbridge, UK.
- Respiratory and Immunology, AstraZeneca, Wilmington, DE, USA.
- Real World Country Solutions, IQVIA Inc, Wayne, PA, USA.
- BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
- Global Medical Affairs, Amgen, Thousand Oaks, CA, USA.
- US Medical Affairs, Amgen, Thousand Oaks, CA, USA.
ORCID-Profile: Christopher S Ambrose, Weily Soong
Zitieren
APA
Zuluaga Sanchez, S., DeMartino, J. K., Gorritz, M., Ambrose, C. S., Tuly, R., Llanos, J. P., Chen, C. C., Lindsley, A. W., Baylis, L., Soong, W., & Tan, L. (2026). Real-World Impact of Tezepelumab on Asthma Exacerbations, Healthcare Resource Utilization, and Costs in US Patients with Severe Asthma: CROSSROADS-1. Journal of Asthma and Allergy, Volume 19, 1-15. https://doi.org/10.2147/jaa.s620862
Vancouver
Zuluaga Sanchez S, DeMartino JK, Gorritz M, Ambrose CS, Tuly R, Llanos JP, et al. Real-World Impact of Tezepelumab on Asthma Exacerbations, Healthcare Resource Utilization, and Costs in US Patients with Severe Asthma: CROSSROADS-1. Journal of Asthma and Allergy. 2026;Volume 19:1-15. doi:10.2147/jaa.s620862
BibTeX
@article{ZuluagaSanchez2026,
author = {Zuluaga Sanchez, Santiago and DeMartino, Jessica K and Gorritz, Magdaliz and Ambrose, Christopher S and Tuly, Rifat and Llanos, Jean-Pierre and Chen, Chi-Chang and Lindsley, Andrew W and Baylis, Lee and Soong, Weily and Tan, Laren},
title = {Real-World Impact of Tezepelumab on Asthma Exacerbations, Healthcare Resource Utilization, and Costs in US Patients with Severe Asthma: CROSSROADS-1},
journal = {Journal of Asthma and Allergy},
year = {2026},
volume = {Volume 19},
pages = {1--15},
doi = {10.2147/jaa.s620862}
}
EUVIMED